001005300 001__ 1005300
001005300 005__ 20240408211951.0
001005300 0247_ $$2doi$$a10.1016/j.ejps.2023.106421
001005300 0247_ $$2ISSN$$a0928-0987
001005300 0247_ $$2ISSN$$a1879-0720
001005300 0247_ $$2Handle$$a2128/34142
001005300 0247_ $$2pmid$$a36889654
001005300 0247_ $$2WOS$$aWOS:000956437600001
001005300 037__ $$aFZJ-2023-01412
001005300 082__ $$a610
001005300 1001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b0$$eCorresponding author
001005300 245__ $$aEvaluation of the 18F-Labeled Analog of the Therapeutic All-d-enantiomeric Peptide RD2 for Amyloid β Imaging
001005300 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2023
001005300 3367_ $$2DRIVER$$aarticle
001005300 3367_ $$2DataCite$$aOutput Types/Journal article
001005300 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712566277_21291
001005300 3367_ $$2BibTeX$$aARTICLE
001005300 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001005300 3367_ $$00$$2EndNote$$aJournal Article
001005300 520__ $$aPositron emission tomography (PET) imaging with radiotracers that bind to fibrillary amyloid β (Aβ) deposits is an important tool for the diagnosis of Alzheimer's disease (AD) and for the recruitment of patients into clinical trials. However, it has been suggested that rather than the fibrillary Aβ deposits, it is smaller, soluble Aβ aggregates that exert a neurotoxic effect and trigger AD pathogenesis. The aim of the current study is to develop a PET probe that is capable of detecting small aggregates and soluble Aβ oligomers for improved diagnosis and therapy monitoring. An 18F-labeled radioligand was prepared based on the Aβ-binding d-enantiomeric peptide RD2, which is currently being evaluated in clinical trials as a therapeutic agent to dissolve Aβ oligomers. 18F-labeling was carried out using palladium-catalyzed S-arylation of RD2 with 2-[18F]fluoro-5-iodopyridine ([18F]FIPy). Specific binding of [18F]RD2-cFPy to brain material from transgenic AD (APP/PS1) mice and AD patients was demonstrated with in vitro autoradiography. In vivo uptake and biodistribution of [18F]RD2-cFPy were evaluated using PET analyses in wild-type and transgenic APP/PS1 mice. Although brain penetration and brain wash-out kinetics of the radioligand were low, this study provides proof of principle for a PET probe based on a d-enantiomeric peptide binding to soluble Aβ species.
001005300 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001005300 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x1
001005300 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x2
001005300 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001005300 7001_ $$0P:(DE-Juel1)132740$$aHumpert, Swen$$b1$$ufzj
001005300 7001_ $$0P:(DE-Juel1)131792$$aSchöneck, Michael$$b2$$ufzj
001005300 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b3$$ufzj
001005300 7001_ $$0P:(DE-Juel1)173023$$aBurda, Nicole$$b4$$ufzj
001005300 7001_ $$0P:(DE-Juel1)145165$$aGremer, Lothar$$b5$$ufzj
001005300 7001_ $$0P:(DE-Juel1)171922$$aGering, Ian$$b6$$ufzj
001005300 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b7$$ufzj
001005300 7001_ $$0P:(DE-Juel1)131794$$aShah, N. Jon$$b8$$ufzj
001005300 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b9$$ufzj
001005300 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b10$$ufzj
001005300 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b11$$ufzj
001005300 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b12$$ufzj
001005300 773__ $$0PERI:(DE-600)1483522-8$$a10.1016/j.ejps.2023.106421$$gp. 106421 -$$p106421$$tEuropean journal of pharmaceutical sciences$$v184$$x0928-0987$$y2023
001005300 8564_ $$uhttps://juser.fz-juelich.de/record/1005300/files/1-s2.0-S0928098723000520-main.pdf$$yOpenAccess
001005300 8767_ $$d2023-07-12$$eAPC$$jZahlung erfolgt
001005300 909CO $$ooai:juser.fz-juelich.de:1005300$$pOpenAPC$$popen_access$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$popenaire
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b0$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132740$$aForschungszentrum Jülich$$b1$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131792$$aForschungszentrum Jülich$$b2$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b3$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)173023$$aForschungszentrum Jülich$$b4$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145165$$aForschungszentrum Jülich$$b5$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171922$$aForschungszentrum Jülich$$b6$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b7$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b8$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b9$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b10$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b11$$kFZJ
001005300 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b12$$kFZJ
001005300 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001005300 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x1
001005300 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x2
001005300 9141_ $$y2023
001005300 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001005300 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
001005300 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
001005300 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
001005300 915__ $$0StatID:(DE-HGF)1200$$2StatID$$aDBCoverage$$bChemical Reactions$$d2022-11-18
001005300 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-16T14:28:48Z
001005300 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
001005300 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
001005300 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
001005300 915__ $$0StatID:(DE-HGF)1210$$2StatID$$aDBCoverage$$bIndex Chemicus$$d2022-11-18
001005300 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-16T14:28:48Z
001005300 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001005300 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-18
001005300 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001005300 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
001005300 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-09-16T14:28:48Z
001005300 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
001005300 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PHARM SCI : 2022$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
001005300 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
001005300 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
001005300 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x1
001005300 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x2
001005300 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x3
001005300 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x4
001005300 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x5
001005300 980__ $$ajournal
001005300 980__ $$aVDB
001005300 980__ $$aI:(DE-Juel1)INM-4-20090406
001005300 980__ $$aI:(DE-Juel1)INM-5-20090406
001005300 980__ $$aI:(DE-Juel1)IBI-7-20200312
001005300 980__ $$aI:(DE-Juel1)INM-2-20090406
001005300 980__ $$aI:(DE-Juel1)INM-11-20170113
001005300 980__ $$aI:(DE-82)080010_20140620
001005300 980__ $$aAPC
001005300 980__ $$aUNRESTRICTED
001005300 9801_ $$aAPC
001005300 9801_ $$aFullTexts